A Phase 3, Multicenter, Open-Label Continuation Study to Moderate to Severe Plaque Psoriasis in Subjects Who Completed a Preceding Psoriasis Study With ABT-874.

Trial Profile

A Phase 3, Multicenter, Open-Label Continuation Study to Moderate to Severe Plaque Psoriasis in Subjects Who Completed a Preceding Psoriasis Study With ABT-874.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2014

At a glance

  • Drugs Briakinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 20 Dec 2011 Actual number of patients changed from 2296 to 2301 as reported by ClinicalTrials.gov.
    • 20 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 20 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top